A Systematic Review of p53 as a Prognostic Factor of Survival in Squamous Cell Carcinoma of the Four Main Anatomical Subsites of the Head and Neck
暂无分享,去创建一个
Richard D Riley | Catrin Tudur-Smith | C. Tudur-Smith | R. Riley | S. Tandon | Sankalap Tandon | Mark T Boyd | Terence M Jones | M. Boyd | T. Jones
[1] G. Ogden,et al. p53 over-expression in laryngeal carcinoma is not predictive of response to radiotherapy. , 1997, Oral oncology.
[2] H. Saya,et al. Clinical significance of p53 functional loss in squamous cell carcinoma of the oropharynx , 2000, International journal of cancer.
[3] K. Sasaki,et al. The significance of PCNA and p53 protein in some oral tumors. , 1995, International journal of oral and maxillofacial surgery.
[4] Y. Furuta,et al. Correlation of clinicopathological parameters and biological markers related to apoptosis and proliferative activity with a clinical outcome in squamous cell carcinoma of the larynx treated with concurrent chemoradiotherapy. , 2001, Auris, nasus, larynx.
[5] M. Daidone,et al. Biological markers as indicators of pathological response to primary chemotherapy in oral‐cavity cancers , 1998, International journal of cancer.
[6] David Moher,et al. Addressing Reporting Biases , 2008 .
[7] X. Wang,et al. Overexpression of p53 nuclear protein in premalignant and malignant laryngeal lesions , 1999, European Archives of Oto-Rhino-Laryngology.
[8] L. Sellmann,et al. Prognostic Significance of p53/bcl‐2 Co‐expression in Patients With Laryngeal Squamous Cell Carcinoma , 2000, The Laryngoscope.
[9] A. Cmelak,et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. , 2008, Journal of the National Cancer Institute.
[10] A. Rosman,et al. Prognostic implications of normal (<0.10 ng/ml) and borderline (0.10 to 1.49 ng/ml) troponin elevation levels in critically ill patients without acute coronary syndrome. , 2008, The American journal of cardiology.
[11] J. Jacobs,et al. Prognostic significance of p53 and FHIT in advanced oropharyngeal carcinoma. , 2004, American journal of otolaryngology.
[12] Richard D Riley,et al. Primer: an evidence-based approach to prognostic markers , 2005, Nature Clinical Practice Oncology.
[13] J. Fenton,et al. The history, aetiology and epidemiology of laryngeal carcinoma. , 2001, Clinical otolaryngology and allied sciences.
[14] J. Manola,et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. , 2007, The New England journal of medicine.
[15] C. Cordon-Cardo,et al. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[16] S. Thompson,et al. Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.
[17] W. Sauerbrei,et al. Reporting recommendations for tumor marker prognostic studies (REMARK). , 2005, Journal of the National Cancer Institute.
[18] H. Pai,et al. Overexpression of p53 protein does not predict local-regional control or survival in patients with early-stage squamous cell carcinoma of the glottic larynx treated with radiotherapy. , 1998, International journal of radiation oncology, biology, physics.
[19] C. Hwang,et al. The clinicopathological significance of p53 and p21 expression in squamous cell carcinoma of hypopharyngeal cancer. , 2003, Cancer letters.
[20] E. Campo,et al. p53 expression in normal, dysplastic, and neoplastic laryngeal epithelium. Absence of a correlation with prognostic factors , 1995, The Journal of pathology.
[21] T. Helliwell,et al. p53 protein expression in tumours from head and neck subsites, larynx and hypopharynx, and differences in relationship to survival. , 1998, Clinical otolaryngology and allied sciences.
[22] H. Eckel,et al. Ki‐67 (MIB1), p53, and Lewis‐X (LeuM1) as Prognostic Factors of Recurrence in T1 and T2 Laryngeal Carcinoma , 2000, The Laryngoscope.
[23] P C Lambert,et al. Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future , 2003, British Journal of Cancer.
[24] Orsolya Csuka,et al. Progression of head and neck squamous cell cancer , 2005, Cancer and Metastasis Reviews.
[25] E. Speel,et al. Marked differences in survival rate between smokers and nonsmokers with HPV 16‐associated tonsillar carcinomas , 2008, International journal of cancer.
[26] R. Taylor. 'Mouseyes': an aid to wound measurement using a computer. , 1997, Journal of Wound Care.
[27] M. Nakamizo,et al. Clinical role of p53 and p21WAF1/CIP1 in squamous cell carcinoma of the pyriform sinus. , 1998, Acta oto-laryngologica.
[28] K. Jung,et al. Maspin expression in early oral tongue cancer and its relation to expression of mutant-type p53 and vascular endothelial growth factor (VEGF). , 2007, Oral oncology.
[29] M. Takahara,et al. Inducible nitric oxide synthase expression in various laryngeal lesions in relation to carcinogenesis, angiogenesis, and patients’ prognosis , 2007, Acta oto-laryngologica.
[30] V. Kosma,et al. p53 expression and cell proliferation as prognostic factors in laryngeal squamous cell carcinoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] B. Vojtesek,et al. Discriminating functional and non‐functional p53 in human tumours by p53 and MDM2 immunohistochemistry , 2005, The Journal of pathology.
[32] G. Pruneri,et al. p63 in Laryngeal Squamous Cell Carcinoma: Evidence for a Role of TA-p63 Down-Regulation in Tumorigenesis and Lack of Prognostic Implications of p63 Immunoreactivity , 2002, Laboratory Investigation.
[33] H. Buyukbayram,et al. Prognostic Value of PCNA and Mutant p53 Expression in Laryngeal Squamous Cell Carcinoma , 2004, Cancer investigation.
[34] A. Mizuno,et al. p53, mdm2, and p21 expression in oral squamous cell carcinomas: relationship with clinicopathologic factors. , 2002, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.
[35] N. Malats,et al. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. , 2005, The Lancet. Oncology.
[36] Michele Tarsilla. Cochrane Handbook for Systematic Reviews of Interventions , 2010, Journal of MultiDisciplinary Evaluation.
[37] J. Schiller,et al. Human papillomavirus type 16 E6 increases the degradation rate of p53 in human keratinocytes , 1992, Journal of virology.
[38] N. Konishi,et al. p53 tumor suppressor gene and ras oncogene mutations in hypopharyngeal squamous cell carcinomas. , 1997, International journal of oncology.
[39] W. Sauerbrei,et al. Identification of clinically useful cancer prognostic factors: what are we missing? , 2005, Journal of the National Cancer Institute.
[40] K. Yoneda,et al. Expression of p53 and p21 proteins in oral squamous cell carcinoma: correlation with lymph node metastasis and response to chemoradiotherapy. , 1998, Pathology, research and practice.
[41] T. Ebert,et al. p53 Immunohistochemistry as a Prognostic Marker in Bladder Cancer , 2000, European Urology.
[42] T. Soussi. p53 alterations in human cancer: more questions than answers , 2007, Oncogene.
[43] L. Kowalski,et al. Clinicopathological and immunohistochemical evaluation of oral squamous cell carcinoma in patients with early local recurrence. , 2007, Oral oncology.
[44] T. Abraham,et al. Phenotypic alterations in Rb pathway have more prognostic influence than p53 pathway proteins in oral carcinoma , 2005, Modern Pathology.
[45] R. Lewensohn,et al. Human papilloma virus (HPV) and p53 immunostaining in advanced tonsillar carcinoma--relation to radiotherapy response and survival. , 2001, Anticancer research.
[46] A. Carvalho,et al. Trends in incidence and prognosis for head and neck cancer in the United States: A site‐specific analysis of the SEER database , 2005, International journal of cancer.
[47] J. Wilson,et al. Expression of cyclin-dependent kinase inhibitor p21(WAF1) and p53 tumour suppressor gene in laryngeal cancer. , 2000, Clinical otolaryngology and allied sciences.
[48] Qifeng Yang,et al. Prognostic significance of vascular endothelial growth factor protein levels in T1‐2 N0 laryngeal cancer treated with primary radiation therapy , 2007, Cancer.
[49] A. Robson,et al. Effective Head and Neck Cancer Management, Third Consensus Document 2002 , 2002 .
[50] N. Jović,et al. p53 mutations and human papillomavirus infection in oral squamous cell carcinomas: correlation with overall survival. , 2005, Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery.
[51] Harald zur Hausen,et al. Papillomaviruses in the causation of human cancers - a brief historical account. , 2009, Virology.
[52] M. Olivier,et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database , 2007, Human mutation.
[53] M. Sydes,et al. Practical methods for incorporating summary time-to-event data into meta-analysis , 2007, Trials.
[54] J. Lunec,et al. P53 overexpression in head and neck carcinoma and radiotherapy results. , 1996, International Journal of Radiation Oncology, Biology, Physics.
[55] S. Fisher,et al. P53 overexpression is associated with bulky tumor and poor local control in T1 glottic cancer. , 2000, International journal of radiation oncology, biology, physics.
[56] J. Hornung,et al. Squamous cell carcinoma of the oropharynx: Ki-67 and p53 can identify patients at high risk for local recurrence after surgery and postoperative radiotherapy. , 2000, International journal of radiation oncology, biology, physics.
[57] A. Hanlon,et al. P53 Alteration in Oral Tongue Cancer is Not Significantly Associated with Age at Diagnosis or Tobacco Exposure , 2005, Tumori.
[58] David J Spiegelhalter,et al. A re-evaluation of random-effects meta-analysis , 2009, Journal of the Royal Statistical Society. Series A,.
[59] K. Vousden. Outcomes of p53 activation - spoilt for choice , 2006, Journal of Cell Science.
[60] John P A Ioannidis,et al. Almost all articles on cancer prognostic markers report statistically significant results. , 2007, European journal of cancer.
[61] W. Dinjens,et al. A subset of head and neck squamous cell carcinomas exhibits integration of HPV 16/18 DNA and overexpression of p16INK4A and p53 in the absence of mutations in p53 exons 5–8 , 2003, International journal of cancer.
[62] Paula R Williamson,et al. Aggregate data meta‐analysis with time‐to‐event outcomes , 2002, Statistics in medicine.
[63] Jill Hayden,et al. Evaluation of the Quality of Prognosis Studies in Systematic Reviews , 2006, Annals of Internal Medicine.
[64] D. Caldarelli,et al. Prognostic significance of Bcl‐2 and p53 expression in advanced laryngeal squamous cell carcinoma , 2001, Head & neck.
[65] A. Russo,et al. TP53 mutations and S‐phase fraction but not DNA‐ploidy are independent prognostic indicators in laryngeal squamous cell carcinoma , 2006, Journal of cellular physiology.
[66] S. Furukawa,et al. An analysis of the prognostic significance of p53 status for squamous cell carcinoma of the oral cavity treated by radiotherapy. , 1998, Oral oncology.
[67] J. L. Frank,et al. p53 tumor suppressor oncogene expression in squamous cell carcinoma of the hypopharynx , 1994, Cancer.
[68] John P A Ioannidis,et al. Selective reporting biases in cancer prognostic factor studies. , 2005, Journal of the National Cancer Institute.
[69] C. Tsien,et al. EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[70] J. Riera,et al. Detection of p53 protein in oropharyngeal carcinoma. Prognostic implications. , 1996, Archives of otolaryngology--head & neck surgery.
[71] M. Boyd,et al. p53: a molecular marker for the detection of cancer. , 2008, Expert opinion on medical diagnostics.
[72] D G Altman,et al. Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis, and beyond , 2009, British Journal of Cancer.
[73] F. Bosch,et al. Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control , 2002, Oncogene.
[74] H. Saito,et al. Expression of protein p27 is associated with progression and prognosis in laryngeal cancer , 1999, The Laryngoscope.
[75] F. Sarkar,et al. Prognostic significance of p53 gene mutations in laryngeal cancer , 1999, The Laryngoscope.
[76] R. Rezola,et al. p53 and Cyclin D1 as Prognostic Factors in Squamous Cell Carcinoma of the Larynx , 2003, The Laryngoscope.